R. Li

MiroMind Team, S. Bai, L. Bing et al.

We present MiroThinker-1.7, a new research agent designed for complex long-horizon reasoning tasks. Building on this foundation, we further introduce MiroThinker-H1, which extends the agent with heavy-duty reasoning capabilities for more reliable multi-step problem solving. In particular, MiroThinker-1.7 improves the reliability of each interaction step through an agentic mid-training stage that emphasizes structured planning, contextual reasoning, and tool interaction. This enables more effective multi-step interaction and sustained reasoning across complex tasks. MiroThinker-H1 further incorporates verification directly into the reasoning process at both local and global levels. Intermediate reasoning decisions can be evaluated and refined during inference, while the overall reasoning trajectory is audited to ensure that final answers are supported by coherent chains of evidence. Across benchmarks covering open-web research, scientific reasoning, and financial analysis, MiroThinker-H1 achieves state-of-the-art performance on deep research tasks while maintaining strong results on specialized domains. We also release MiroThinker-1.7 and MiroThinker-1.7-mini as open-source models, providing competitive research-agent capabilities with significantly improved efficiency.

R. Li, J. Liu, X. L. Deng et al.

The diagnosis and monitoring of Castrate Resistant Prostate Cancer (CRPC) are crucial for cancer patients, but the current models (such as P-NET) have limitations in terms of parameter count, generalization, and cost. To address the issue, we develop a more accurate and efficient Prostate Cancer patient condition prediction model, named PR-NET. By compressing and optimizing the network structure of P-NET, the model complexity is reduced while maintaining high accuracy and interpretability. The PR-NET demonstrated superior performance in predicting prostate cancer patient outcomes, outshining P-NET and six other traditional models with a significant margin. In our rigorous evaluation, PR-NET not only achieved impressive average AUC and Recall scores of 0.94 and 0.83, respectively, on known data but also maintained robust generalizability on five unknown datasets with a higher average AUC of 0.73 and Recall of 0.72, compared to P-NET's 0.68 and 0.5. PR-NET's efficiency was evidenced by its shorter average training and inference times, and its gene-level analysis revealed 46 key genes, demonstrating its enhanced predictive power and efficiency in identifying critical biomarkers for prostate cancer. Future research can further expand its application domains and optimize the model's performance and reliability.